[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-370532-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-370532-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","drp2-promotes-emt-and-serves-as-a-potential-therapeutic-target-for-luad-treatment","DRP2 promotes EMT and serves as a potential therapeutic target for LUAD treatment","","DRP2 was investigated as a molecular contributor to lung adenocarcinoma (LUAD) progression and a possible therapeutic target. Elevated DRP2 expression was profiled in LUAD using bioinformatics and then confirmed by immunohistochemistry, quantitative PCR, and Western blot. Functional studies in vitro and in vivo assessed proliferation, cell cycle, invasion and migration using multiple cell assays and mouse xenograft/metastasis models. High DRP2 correlated with worse survival, while DRP2 knockdown accelerated LUAD progression via the EMT pathway.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/drp2-promotes-emt-and-serves-as-a-potential-therapeutic-target-for-luad-treatment/370532/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/drp2-promotes-emt-and-serves-as-a-potential-therapeutic-target-for-luad-treatment/370532.png","ImageObject",300,407,{"name":42,"@type":43},"Sophia Brooks","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How was DRP2 expression in LUAD assessed and validated?","Question",{"text":63,"@type":64},"DRP2 expression patterns were analyzed with bioinformatics tools, then validated using immunohistochemical staining, quantitative PCR, and Western blot analyses.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What relationship was found between DRP2 levels and patient prognosis?",{"text":68,"@type":64},"High DRP2 expression in LUAD was strongly correlated with poorer survival.",{"name":70,"@type":61,"acceptedAnswer":71},"What effect does DRP2 knockdown have on LUAD progression?",{"text":72,"@type":64},"DRP2 knockdown accelerated LUAD progression through the EMT pathway.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},370532,1790872917,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962084925636,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nDRP2 promotes EMT and serves asa potential therapeutic target for LUAD treatment  \nZhimeng Chen1,2,4, Hao Shi3,4, Wenxuan Hu1,2,4, JianYang1,2, Yuxuan Xing1,2, Xin Lv1,2, Chenzhuo Wu1,2, Cheng Ding1,2􀀍 & Jun Zhao1,2􀀍  \nLUAD, a prevalent lung cancer with high mortality, has seen increased focus on molecular targeted therapies due to patient heterogeneity. Among these prospects, dystrophin-associated protein 2 (DRP2), a critical component of the dystrophin complex, underpins membrane-associated structures vital for intercellular interactions in vertebrates. Aberrations in DRP2 function have been linked to the occurrence and development of multiple diseases, prompting an inquiry into its potential link with LUAD progression. To delve into the potential roles of DRP2 in LUAD, we initiated a comprehensive investigation. First, we analyzed DRP2 expression patterns in LUAD using bioinformatics tools. This was subsequently validated through immunohistochemical staining, quantitative PCR, and Western blot analyses. Furthermore, we assessed the functional implications of DRP2 in LUAD cells, both in vitro and in vivo, utilizing assays such as cell cycle analysis, CCK-8 proliferation assay, Colony formation assay EdU incorporation, Transwell migration test, scratch wound healing assay, flow cytometry, and mouse models for tumor xenograft and metastasis. Results showed a strong correlation between high DRP2 expression in LUAD and poorer survival. Notably, DRP2 knockdown accelerated LUAD progression via the EMT pathway. These findings highlight DRP2’s crucial role in LUAD and its potential as a therapeutic target.  \nKeywords DRP2, Lung adenocarcinoma, EMT, Cell cycle, Invasion, Migration  \nDespite notable advancementsin lung cancer treatment in recent times, lung cancer continues topose a formidable threat to human life and health, ranking as the leading cause of mortality globally1. In various lung cancer types, NSCLC comprises approximately 85% and represents the primary pathological subtype2. The intricate nature of NSCLC’s proliferation and metastasis mechanisms has hindered significant improvements in patient prognosis, resulting in a dismal five-year survival rate of merely 20%3. Notably, LUAD constitutes a significant majority of NSCLC cases. Although molecular targeted therapies and immunotherapies have significantly enhanced LUAD patient outcomes, not all LUAD patients harbor suitable molecular targets for these treatments3–5. Consequently, we hope that novel potential molecules capable of predicting LUAD prognosis, unravel the underlying molecular mechanisms regulating its progression, and devise effective, targeted therapeutic strategies.  \nDRP2, or Dystrophin Related Protein-2, belongs to the dystrophin gene family and is encoded by a 45-kilobase gene positioned on the Xp22 region. Its primary expression sites are the brain and spinal cord. Structurally akin to Dp116, DRP2 is suggested to execute analogous functions within the vertebrate central nervous system6. Beyond this, DRP2 assumes a vital part in the peripheral nervous system, collaborating with periaxin and gluconic anhydride, forming PDG. This complex contributes to the preservation of the Cajal band in myelin Schwann cells, emphasizing DRP2’s role7.Notably, Charcot-Marie-Tooth disease (CMT), a prevalent hereditary neurological condition with a frequency of around 1 in 2,500, arises from DRP2 deficiency, resulting in the disintegration of the Cajal band in affected individuals8,9.Moreover, DRP2 is a cornerstone molecule in the extracellular matrix-receptor interaction cascade and has garnered attention for its potential involvement in oncogenesis10. However, the exact expression patterns and functional contributions of DRP2 in LUAD have remained enigmatic. Hence, this study endeavors to clarify the expression status of DRP2 in LUAD and elucidate its pivotal role in cancer progression.  \n1Dep","cbCaiaK45mJOlen3","https://ap.wps.com/l/cbCaiaK45mJOlen3","pdf",2798060,13,"English","# Materials and methods\n## Data collection\n## The cBioPortal analysis\n## Kaplan–Meier survival analysis","[{\"question\":\"How was DRP2 expression in LUAD assessed and validated?\",\"answer\":\"DRP2 expression patterns were analyzed with bioinformatics tools, then validated using immunohistochemical staining, quantitative PCR, and Western blot analyses.\"},{\"question\":\"What relationship was found between DRP2 levels and patient prognosis?\",\"answer\":\"High DRP2 expression in LUAD was strongly correlated with poorer survival.\"},{\"question\":\"What effect does DRP2 knockdown have on LUAD progression?\",\"answer\":\"DRP2 knockdown accelerated LUAD progression through the EMT pathway.\"}]","DRP2 promotes EMT and serves as a potential therapeutic target for LUAD treatment | PDF",1790189019,33,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/11d7a8d4b0bd5679f925f514f7bb90a7.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a38aa018517097e15ae9c8ffb509c215.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/69390b30123399c9f40c86d8bfd3622b.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/33b265d5ae18780aa70a3c0d3e9b6199.webp",980,1287]